Personalized non-invasive magnetic and electrical stimulation of memory networks in mild Alzheimer's

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

People with mild, biomarker-confirmed Alzheimer's will be randomized to receive personalized intermittent theta-burst rTMS (iTBS) plus tACS, iTBS with sham tACS, or double sham. Stimulation targets Default Mode Network regions such as the precuneus and is delivered noninvasively using individualized protocols. Outcomes include cognitive and behavioral testing, plasma biomarkers (baseline, week 12, week 24), MRI, TMS-EEG, and immersive virtual environment assessments, with visits at baseline, week 12, and week 24. Safety monitoring and adverse event recording are performed throughout the approximately six-month participation period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with a diagnosis of AD according to IWG criteria
* 20 \> MMSE \< 28
* Patients with CSF specific biomarker profile or with a positive Amyloid Pet Scan consistent with the presence of amyloid pathology
* Global Clinical Dementia Rating (CDR) ≤1
* Previous decline in cognition for more than six months as documented in patient medical records
* A caregiver available and living in the same household or interacting with the patient and available
* Patients living at home or nursing home setting without continuous nursing care
* General health status acceptable for a participation in a 6-month clinical trial
* Stable pharmacological treatment for at least one month prior to screening
* No regular intake of prohibited medications.
* Signed informed consent by the patient. If there are any doubts that the patient is mentally capable of giving informed consent, the patient will be examined and verified to be mentally capable by an independent physician/ neurologist, prior to the initiation of any study specific procedure. Signed consent of the caregiver

Exclusion Criteria:

* Failure to undergo screening or baseline exams
* Hospitalization or change in chronic concomitant medications one month before the screening or during the screening period
* Clinical, laboratory, or neuroimaging results consistent with:

  1. other primary degenerative dementia (Lewy body dementia, frontotemporal dementia, Huntington's disease, Creutzfeldt-Jakob disease, Down syndrome, etc.);
  2. other neurodegenerative conditions (Parkinson's disease, amyotrophic lateral sclerosis, etc.);
  3. orthostatic hypotension and autonomic disorders
  4. cerebrovascular disease (major infarction, a strategic infarction or multiple lacunar infarctions, extensive white matter lesions \> one quarter of total white matter);
  5. other central nervous system diseases (severe traumatic brain injury, tumors, subdural hematoma, or other space-occupying processes, etc.);
  6. seizure disorder.
  7. Other infectious, metabolic, or systemic diseases affecting the central nervous system (syphilis, existing hypothyroidism, current vitamin B12 or folate deficiency, serum electrolytes outside normal limits, juvenile diabetes, etc.).
* A current DSM-V diagnosis of major depression, schizophrenia, or bipolar disorder.
* Clinically significant, advanced, or unstable disease that may interfere with primary or secondary variable assessments and may affect the assessment of the patient's clinical or mental state, or expose the patient to special risk, such as:

  1. Disability that may prevent the patient from completing all study requirements (e.g., blindness, deafness, severe language difficulties, etc.);
  2. Opioid-containing analgesics
  3. Suspected or known drug or alcohol abuse, i.e., more than about 60 g of alcohol (about 1 liter of beer or 500 ml of wine) per day, indicated by a high mean corpuscular volume (MCV) above the normal value at screening;
  4. Any condition that, in the investigator's judgment, makes the patient unsuitable for inclusion

Where it's running

• IRCCS Santa Lucia Foundation
  Rome, Italy, Italy Recruiting
• I.R.C.C.S. Centro Neurolesi Bonino Pulejo
  Messina, Sicily, Italy Not yet recruiting

Study contacts

• Principal investigator: Giacomo Koch, Prof. — IRCCS Santa Lucia Foundation
• Study coordinator: Giacomo Koch, Prof
• Email: g.koch@hsantlucia.it
• Phone: +390651501181

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood biomarker cohort for memory disorders in older adults

  This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.

  Recruiting Yonsei University · Seoul, Seodamun-gu · NCT07880275

• Tau changes after hip or knee replacement surgery

  Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.

  Recruiting Uppsala University Hospital · Uppsala · NCT07871487

• Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Mild Alzheimer's Dementia

  This study will test whether a low-dose brain radiation treatment using HeLaXON helps people with mild Alzheimer's dementia improve or stabilize thinking and daily function.

  Recruiting ReadyCure Inc. · Cheonan, Chungcheongnam-do · NCT07863011

• Cervical lymphatic surgery to see if it helps people with mild Alzheimer’s

  We’re testing a surgical approach in people with mild Alzheimer’s to see if creating alternative neck lymph drainage routes can affect brain biomarkers and daily function.

  Recruiting at 2 sites Maliszewski Daniel · Gdansk and 1 other locations · NCT07857759

• Transcranial random noise stimulation for behavioral and psychological symptoms in Alzheimer's disease

  This trial tests whether high-frequency transcranial random noise stimulation can help people with early Alzheimer's disease who have BPSD, compared to a sham treatment.

  Recruiting Anhui Medical University · Hefei, Anhui · NCT07827196

• Testing LY4405094 in healthy people and people with Alzheimer’s disease

  This study tests LY4405094 to see if it is safe and how it behaves in the body, including how it reaches the brain fluid in healthy participants and how it affects a brain protein in people with Alzheimer's disease.

  Recruiting Phase 1 Eli Lilly and Company · Anaheim, California and 17 other locations · NCT07787182

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.